---
title: "Fennec Pharmaceuticals former director Rosty Raykov disposes of 10,000 common shares worth $95,800"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294863436.md"
description: "Fennec Pharmaceuticals former director Rosty Raykov sold 10,000 common shares at $9.58 per share on August 3, totaling $95,800. Post-transaction, he holds 131,633 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on September 19, 2025. This information was published via EDGAR by Fennec Pharmaceuticals Inc."
datetime: "2026-08-04T20:06:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294863436.md)
  - [en](https://longbridge.com/en/news/294863436.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294863436.md)
generator: "portal-rs"
---

# Fennec Pharmaceuticals former director Rosty Raykov disposes of 10,000 common shares worth $95,800

-   Former director Rosty Raykov sold 10,000 common shares of Fennec Pharmaceuticals on Aug. 3 at USD 9.58. \* Raykov held 131,633 common shares following the transaction. \* The sale was executed under a Rule 10b5-1 trading plan adopted on Sept. 19, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001468316-26-000021), on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FENC.US](https://longbridge.com/en/quote/FENC.US.md)

## Related News & Research

- [Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention](https://longbridge.com/en/news/296143499.md)
- [Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand](https://longbridge.com/en/news/295527022.md)
- [Arrowhead Pharma director Michael S. Perry disposes of 11,600 shares for $1.01 million](https://longbridge.com/en/news/296537943.md)
- [Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19](https://longbridge.com/en/news/296655292.md)
- [Apimeds Pharmaceuticals US gains Apitox rights in assignment from South Korea’s FreeT](https://longbridge.com/en/news/296653985.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**